OBJECTIVE: To investigate the potential contribution of germline sequence alterations in the BAP1 gene in uveal melanoma (UM) patients with possible predisposition to hereditary cancer. DESIGN: A total of 53 unrelated UM patients with high risk for hereditary cancer and five additional family members of one proband were studied. Mutational screening was carried out by direct sequencing. RESULTS: Of the 53 UM patients studied, a single patient was identified with a germline BAP1 truncating mutation, c. 799 C→T (p.Q267X), which segregated in several family members and was associated with UM and other cancers. Biallelic inactivation of BAP1 and decreased BAP1 expression were identified in the UM, lung adenocarcinoma and meningioma tumours from three family members with this germline BAP1 mutation. Germline BAP1 variants of uncertain significance, likely non-pathogenic, were also identified in two additional UM patients. CONCLUSION: This study reports a novel hereditary cancer syndrome caused by a germline BAP1 mutation that predisposes patients to UM, lung carcinoma, meningioma, and possibly other cancers. The results indicate that BAP1 is the candidate gene in only a small subset of hereditary UM, suggesting the contribution of other candidate genes.
OBJECTIVE: To investigate the potential contribution of germline sequence alterations in the BAP1 gene in uveal melanoma (UM) patients with possible predisposition to hereditary cancer. DESIGN: A total of 53 unrelated UM patients with high risk for hereditary cancer and five additional family members of one proband were studied. Mutational screening was carried out by direct sequencing. RESULTS: Of the 53 UM patients studied, a single patient was identified with a germline BAP1 truncating mutation, c. 799 C→T (p.Q267X), which segregated in several family members and was associated with UM and other cancers. Biallelic inactivation of BAP1 and decreased BAP1 expression were identified in the UM, lung adenocarcinoma and meningioma tumours from three family members with this germline BAP1 mutation. Germline BAP1 variants of uncertain significance, likely non-pathogenic, were also identified in two additional UM patients. CONCLUSION: This study reports a novel hereditary cancer syndrome caused by a germline BAP1 mutation that predisposes patients to UM, lung carcinoma, meningioma, and possibly other cancers. The results indicate that BAP1 is the candidate gene in only a small subset of hereditary UM, suggesting the contribution of other candidate genes.
Authors: D E Jensen; M Proctor; S T Marquis; H P Gardner; S I Ha; L A Chodosh; A M Ishov; N Tommerup; H Vissing; Y Sekido; J Minna; A Borodovsky; D C Schultz; K D Wilkinson; G G Maul; N Barlev; S L Berger; G C Prendergast; F J Rauscher Journal: Oncogene Date: 1998-03-05 Impact factor: 9.867
Authors: J William Harbour; Michael D Onken; Elisha D O Roberson; Shenghui Duan; Li Cao; Lori A Worley; M Laurin Council; Katie A Matatall; Cynthia Helms; Anne M Bowcock Journal: Science Date: 2010-11-04 Impact factor: 47.728
Authors: Mohamed H Abdel-Rahman; Robert Pilarski; James B Massengill; Benjamin N Christopher; Ryan Noss; Frederick H Davidorf Journal: Melanoma Res Date: 2011-06 Impact factor: 3.599
Authors: B Buecher; M Gauthier-Villars; L Desjardins; L Lumbroso-Le Rouic; C Levy; A De Pauw; J Bombled; C Tirapo; C Houdayer; B Bressac-de Paillerets; D Stoppa-Lyonnet Journal: Fam Cancer Date: 2010-12 Impact factor: 2.375
Authors: Sebastian Walpole; Antonia L Pritchard; Colleen M Cebulla; Robert Pilarski; Meredith Stautberg; Frederick H Davidorf; Arnaud de la Fouchardière; Odile Cabaret; Lisa Golmard; Dominique Stoppa-Lyonnet; Erin Garfield; Ching-Ni Njauw; Mitchell Cheung; Joni A Turunen; Pauliina Repo; Reetta-Stiina Järvinen; Remco van Doorn; Martine J Jager; Gregorius P M Luyten; Marina Marinkovic; Cindy Chau; Miriam Potrony; Veronica Höiom; Hildur Helgadottir; Lorenza Pastorino; William Bruno; Virginia Andreotti; Bruna Dalmasso; Giulia Ciccarese; Paola Queirolo; Luca Mastracci; Karin Wadt; Jens Folke Kiilgaard; Michael R Speicher; Natasha van Poppelen; Emine Kilic; Rana'a T Al-Jamal; Irma Dianzani; Marta Betti; Carsten Bergmann; Sandro Santagata; Sonika Dahiya; Saleem Taibjee; Jo Burke; Nicola Poplawski; Sally J O'Shea; Julia Newton-Bishop; Julian Adlard; David J Adams; Anne-Marie Lane; Ivana Kim; Sonja Klebe; Hilary Racher; J William Harbour; Michael L Nickerson; Rajmohan Murali; Jane M Palmer; Madeleine Howlie; Judith Symmons; Hayley Hamilton; Sunil Warrier; William Glasson; Peter Johansson; Carla Daniela Robles-Espinoza; Raul Ossio; Annelies de Klein; Susana Puig; Paola Ghiorzo; Maartje Nielsen; Tero T Kivelä; Hensin Tsao; Joseph R Testa; Pedram Gerami; Marc-Henri Stern; Brigitte Bressac-de Paillerets; Mohamed H Abdel-Rahman; Nicholas K Hayward Journal: J Natl Cancer Inst Date: 2018-12-01 Impact factor: 13.506
Authors: Jill A Ohar; Mitchell Cheung; Jacqueline Talarchek; Suzanne E Howard; Timothy D Howard; Mary Hesdorffer; Hongzhuang Peng; Frank J Rauscher; Joseph R Testa Journal: Cancer Res Date: 2015-12-30 Impact factor: 12.701
Authors: Marjorie G Zauderer; Matthew Bott; Robert McMillan; Camelia S Sima; Valerie Rusch; Lee M Krug; Marc Ladanyi Journal: J Thorac Oncol Date: 2013-11 Impact factor: 15.609
Authors: Suganth Suppiah; Farshad Nassiri; Wenya Linda Bi; Ian F Dunn; Clemens Oliver Hanemann; Craig M Horbinski; Rintaro Hashizume; Charles David James; Christian Mawrin; Houtan Noushmehr; Arie Perry; Felix Sahm; Andrew Sloan; Andreas Von Deimling; Patrick Y Wen; Kenneth Aldape; Gelareh Zadeh Journal: Neuro Oncol Date: 2019-01-14 Impact factor: 12.300